Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EQL Pharma ABOSTO:EQL -7.20%42 EV-to-EBIT is 19.61 as of Aug. 05, 2026, which is 52% below its 10-year median of 41.12. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 690 Drug Manufacturers companies, EQL Pharma AB ranks worse than 57.97% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
EQL Pharma AB's Enterprise Value for the quarter that ended in Mar. 2026 was kr1,979.0 Mil.
EQL Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr48.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EQL Pharma AB EV-to-EBIT Related Terms
EQL Pharma AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's EV-to-EBIT falls into.
EQL Pharma AB's current Enterprise Value is kr954.9 Mil.
EQL Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr48.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EQL Pharma AB (OSTO:EQL) has a EV-to-EBIT of 19.61 as of Aug. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on EQL Pharma AB and its competitors. This is 52% below median its historical median of 41.12. Over the past decade, EQL Pharma AB's EV-to-EBIT has ranged from 19.61 to 53.90. According to the industry distribution chart, EQL Pharma AB ranks #400 out of 690 companies in the Drug Manufacturers industry, placing it in the top 58%.
Is EQL Pharma AB's EV-to-EBIT too high?
EQL Pharma AB's current EV-to-EBIT of 19.61 is 52% below median its 10-year median of 41.12. Over the past 10 years, this metric has ranged from a low of 19.61 to a high of 53.90. The Drug Manufacturers industry median EV-to-EBIT is 15.57. EQL Pharma AB's value of 19.61 is 25.9% above this industry median. Based on the distribution chart, EQL Pharma AB ranks #400 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #400 out of 690 companies for EV-to-EBIT. This places EQL Pharma AB in the lower half of its industry. The industry median EV-to-EBIT is 15.57. EQL Pharma AB's value of 19.61 is 25.9% above this benchmark. Historically, EQL Pharma AB's own EV-to-EBIT has ranged from 19.61 to 53.90 over the past decade. While the company's 10-year median is 41.12 vs. the industry median of 15.57, EQL Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.57, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EQL Pharma AB's current EV-to-EBIT of 19.61 is 25.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current EV-to-EBIT is 19.61, which is 52% below median its own 10-year median of 41.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current EV-to-EBIT of 19.61. The current EV-to-EBIT is 19.61, which is 52% below median its 10-year median of 41.12 and 25.9% above the Drug Manufacturers industry median of 15.57. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current EV-to-EBIT is 19.61 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
